# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Lorraine Hansberry (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML034-SYN-TD
- Date: 1963-06-29
- Fictional facility: St. Posthumous Health Center
- Fictional author: Odette Marchetti-Fields, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Review on day 1 of cycle 4 of modified FOLFIRINOX. **S**

## History of present illness

Ms. Hansberry returns on the first day of her fourth cycle; cycles 1 to 3 were given on schedule. After each cycle she has nausea for a day or two, controlled with olanzapine at night, and two or three loose stools on days 3 to 5, settled with loperamide. For a few days after each cycle cold drinks hurt her throat and her fingers and toes tingle in the cold, and the fingertips now tingle mildly between cycles; she can still type and do buttons. Pain is 2 out of 10 with one or two oxycodone tablets a day, and she sleeps through. She writes three mornings a week. Her stools are formed with pancrelipase and her weight is steady. Home fasting glucose readings are 110 to 130 mg/dL. She has had no bleeding or black stools since the iron. The germline panel and the tumor profile have both resulted. She has had no thoughts of self-harm. **S**

| Element | Detail |
|---|---|
| Treatment | Cycles 1 to 3 on schedule; cycle 4 today |
| Effects | Nausea one or two days; loose stools days 3 to 5; cold-induced tingling, now mild between cycles |
| Genetic results | Germline panel negative; tumor KRAS G12D, TP53 and CDKN2A alterations, microsatellite stable, no BRCA1, BRCA2 or PALB2 variant, no NTRK, NRG1 or ALK fusion |
| Pain | 2 out of 10 on oxycodone once or twice a day |
| Writing | Three mornings a week |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired for three days after each cycle; weight 54.8 kg; no fever |
| Gastrointestinal | Positive | Nausea one or two days per cycle; loose stools days 3 to 5; no black stools |
| Neurological | Positive | Cold-induced tingling after each cycle; mild fingertip tingling between cycles; no weakness |
| Hematologic and lymphatic | Negative | No bleeding or bruising |
| Cardiovascular | Negative | No leg swelling or calf pain |
| Psychiatric | Positive | Worried before each scan and test; PHQ-9 8, GAD-7 9; no thoughts of self-harm |

6 systems reviewed. **S**

## Current medications

- Pantoprazole 40 mg delayed-release oral tablet, one tablet by mouth once daily before breakfast **S**
- Oxycodone 5 mg oral tablet, one tablet by mouth every 4 hours as needed for pain **S**
- Senna 8.6 mg oral tablet, two tablets by mouth at night while taking oxycodone **S**
- Pancrelipase delayed-release capsule (lipase 36,000 units), two capsules with each meal and one with each snack **S**
- Oxaliplatin 5 mg/mL injection, 135 mg (85 mg/m2) intravenously over 2 hours on day 1 of each 14-day cycle, for six cycles **S**
- Irinotecan 20 mg/mL injection, 238 mg (150 mg/m2) intravenously over 90 minutes on day 1 of each 14-day cycle, cycles 1 to 5 **S**
- Leucovorin 10 mg/mL injection, 634 mg (400 mg/m2) intravenously over 2 hours on day 1 of each 14-day cycle, for six cycles **S**
- Fluorouracil 50 mg/mL injection, 3800 mg (2400 mg/m2) by continuous infusion over 46 hours through the port from day 1 of each 14-day cycle, for six cycles, with no bolus **S**
- Pegfilgrastim 6 mg/0.6 mL prefilled syringe, 6 mg under the skin on day 3 of each cycle, after the pump is disconnected **S**
- Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea **S**
- Olanzapine 5 mg oral tablet, one tablet by mouth at night on days 1 to 4 of each cycle **S**
- Loperamide 2 mg oral capsule, two capsules at the first loose stool, then one after each loose stool, no more than eight a day unless directed **S**
- Apixaban 2.5 mg oral tablet, one tablet by mouth twice daily during chemotherapy, stopped three days before surgery **S**

## Allergies

- No known allergy **S**

## Objective

BP 110/70 mmHg; pulse 84 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 54.8 kg; BMI 20.6 kg/m². All vital signs are synthetic.

Hemoglobin: 11.2 g/dL (low); White cell count: 8.9 10*3/uL; Absolute neutrophil count: 5.8 10*3/uL; Platelets: 214 10*3/uL; Creatinine: 0.72 mg/dL; eGFR (CKD-EPI 1958): 114 mL/min/1.73 m²; Glucose: 128 mg/dL (high); ALT: 26 U/L; AST: 27 U/L; Alkaline phosphatase: 120 U/L (high); Total bilirubin: 0.6 mg/dL; Albumin: 3.5 g/dL; Magnesium: 1.9 mg/dL; Ferritin: 88 ng/mL; CA 19-9: 210 U/mL (high); PHQ-9: 8; GAD-7: 9; Pain score (0 to 10): 2. All results are synthetic.

## Change since baseline

- Hemoglobin: 9.1 g/dL (low) at baseline, 11.2 g/dL (low) at this visit **S**
- White cell count: 7.4 10*3/uL at baseline, 8.9 10*3/uL at this visit **S**
- Platelets: 388 10*3/uL at baseline, 214 10*3/uL at this visit **S**
- Creatinine: 0.7 mg/dL at baseline, 0.72 mg/dL at this visit **S**
- eGFR (CKD-EPI 1958): 118 mL/min/1.73 m² at baseline, 114 mL/min/1.73 m² at this visit **S**
- Glucose: 132 mg/dL (high) at baseline, 128 mg/dL (high) at this visit **S**
- ALT: 48 U/L (high) at baseline, 26 U/L at this visit **S**
- AST: 41 U/L (high) at baseline, 27 U/L at this visit **S**
- Alkaline phosphatase: 236 U/L (high) at baseline, 120 U/L (high) at this visit **S**
- Total bilirubin: 1.6 mg/dL (high) at baseline, 0.6 mg/dL at this visit **S**
- Albumin: 3.6 g/dL at baseline, 3.5 g/dL at this visit **S**
- Ferritin: 6 ng/mL (low) at baseline, 88 ng/mL at this visit **S**
- Pain score (0 to 10): 5 at baseline, 2 at this visit **S**

## Immunizations given today

- Recombinant zoster vaccine, dose 2 of 2 **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 54.8 kg; blood pressure 110/70, pulse 84 |
| Eyes | No icterus |
| Abdomen | Mild epigastric tenderness; port site clean |
| Neurological | Light touch slightly reduced at the fingertips; vibration sense and reflexes normal; fine finger movements normal (grade 1 sensory neuropathy) |
| Extremities | No leg swelling |
| Psychiatric | Engaged, dry humor, organized |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Pancreatic head adenocarcinoma, borderline resectable, on modified FOLFIRINOX** (C25.0). Responding by marker: CA 19-9 210 U/mL from 486. The germline panel is negative, so there is no inherited variant to pass on and no reason for platinum or PARP inhibitor choices based on one; the tumor carries the usual KRAS G12D change with no targetable alteration, so modified FOLFIRINOX remains the right treatment. Counts, kidney and liver function allow full doses today: neutrophils 5.8 with pegfilgrastim, platelets 214, creatinine 0.72 mg/dL, bilirubin 0.6 mg/dL. Hepatitis B, hepatitis C and HIV tests before cycle 1 were negative. **S**
   - Cycle 4 at full dose today.
   - Interim restaging CT in two weeks, before cycle 5.
   - Second recombinant zoster dose given today.
2. **Oxaliplatin neuropathy, grade 1** (G62.0). Grade 1 sensory neuropathy, persisting mildly between cycles. No drug prevents it; the dose is continued at grade 1 and reduced or stopped if it reaches grade 2 or affects her hands. **S**
   - Avoid cold drinks and use gloves for the days after each cycle.
   - Check before each oxaliplatin dose.
3. **Iron deficiency anemia from blood loss** (D50.0). Hemoglobin 11.2 g/dL and ferritin 88 ng/mL: iron stores replaced; no bleeding for eight weeks. **S**
   - Blood count with each cycle.
4. **Diabetes due to the pancreatic cancer** (E08.9). Glucose 128 mg/dL; home fasting readings 110 to 130; no treatment needed yet. **S**
   - A1c with the restaging tests.
5. **Cancer-related pain** (G89.3). Controlled: 2 out of 10 on one or two oxycodone tablets a day, with a clear head. **S**
   - Continue; review with palliative care monthly.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count with neutrophils and platelets | Before each chemotherapy cycle and at each visit | Completed today | Hemoglobin 11.2 g/dL, white cells 8.9, neutrophils 5.8, platelets 214; full dose |
| Laboratory | Kidney and liver function, albumin | Before each cycle | Completed today | Creatinine 0.72 mg/dL, eGFR 114; ALT 26, AST 27, alkaline phosphatase 120 U/L, bilirubin 0.6 mg/dL; albumin 3.5 g/dL |
| Laboratory | Magnesium | Before each cycle | Completed today | 1.9 mg/dL |
| Laboratory | Ferritin after intravenous iron | Four to eight weeks after the last dose | Completed today | 88 ng/mL |
| Laboratory | CA 19-9 | At diagnosis after biliary drainage, every two cycles during treatment, before surgery, after surgery, then every three to six months | Completed today | 210 U/mL, from 486 at diagnosis |
| Imaging | Interim restaging CT | Every two months during chemotherapy before surgery | Ordered | Ordered today for two weeks from now, before cycle 5 |
| Laboratory | Germline multigene panel | Once, at diagnosis | Up to date | Negative for pathogenic variants; reviewed with the genetic counselor; no cascade testing needed |
| Laboratory | Tumor molecular profiling | At diagnosis | Up to date | KRAS G12D, TP53 and CDKN2A alterations; microsatellite stable; no BRCA1, BRCA2 or PALB2 variant; no NTRK, NRG1 or ALK fusion |
| Laboratory | Hepatitis B, hepatitis C and HIV screening | Before chemotherapy | Up to date | Negative before cycle 1; hepatitis B surface antibody negative, so vaccination after chemotherapy |
| Examination | Oxaliplatin neuropathy: symptoms and examination | Before each oxaliplatin dose | Completed today | Grade 1 sensory neuropathy; full dose continues |
| Medication safety | Nausea, vomiting and diarrhea control | Each cycle | Completed today | Nausea one or two days on olanzapine; loose stools controlled with loperamide |
| Medication safety | Venous thromboembolism prophylaxis | During chemotherapy | Completed today | No bleeding for eight weeks and hemoglobin 11.2 g/dL: apixaban 2.5 mg twice daily started today, with teaching on bleeding signs |
| Survey | Pain score and opioid review | Each visit | Completed today | Pain 2 out of 10 |
| Self-management | Weight, nutrition and enzyme replacement | Each visit | Completed today | Weight 54.8 kg, 1 percent below the weight at diagnosis; stools formed on pancrelipase |
| Laboratory | Glucose and home readings | Each visit and before each cycle | Completed today | Glucose 128 mg/dL; home fasting 110 to 130 |
| Examination | Dilated eye examination and urine albumin-to-creatinine ratio | At diagnosis of diabetes, then yearly | Deferred | A deviation: the dilated eye examination and urine albumin-to-creatinine ratio planned when diabetes was diagnosed were not arranged, amid staging and the start of chemotherapy. Harm is unlikely after two months of mild diabetes, but the check is a standard of care. Corrective action: both booked with the visit after surgery, when treatment visits are fewer |
| Survey | Distress and depression screen (PHQ-9, GAD-7) | At diagnosis, at each treatment phase, and when symptoms change | Completed today | PHQ-9 8 and GAD-7 9; worry before scans; she sees the palliative care social worker monthly |

## Goal progress

- Endoscopy and pancreas-protocol CT within one week, tissue diagnosis and biliary drainage within two weeks, and a tumor board plan within three weeks of presentation. Outcome by 1963-05-04: Endoscopy in two days, CT in three, EUS biopsy and stent in one week, tumor board in nine days, consultation at two weeks. **S**
- Germline genetic testing with counseling and tumor molecular profiling resulted before surgery. Outcome by 1963-06-29: Germline panel negative; tumor KRAS G12D, microsatellite stable, no targetable alteration. **S**
- Six cycles of modified FOLFIRINOX before surgery with no delay of more than one week. In progress; target 1963-08-10. **S**
- Resection with clear margins if restaging shows no progression. In progress; target 1963-10-05. **S**
- Pain 3 out of 10 or less with a clear head for writing. Outcome by 1963-06-29: Pain 1 to 2 out of 10 on oxycodone 5 mg once or twice a day. **S**
- Weight kept within 5 percent of the weight at diagnosis through chemotherapy, with enzyme replacement and dietitian support. In progress; target 1963-08-10. **S**
- PHQ-9 below 10 throughout treatment, with support she chooses and palliative care alongside cancer treatment. In progress; target 1963-10-05. **S**

## Medication changes

- Started: Apixaban 2.5 mg oral tablet, one tablet by mouth twice daily during chemotherapy, stopped three days before surgery **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma (2026), National Comprehensive Cancer Network
- Khorana AA, et al. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016;34(21):2541-2556 (PMID 27247221) (2016), American Society of Clinical Oncology
- Stoffel EM, et al. Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol 2019;37(2):153-164 (PMID 30457921) (2019), American Society of Clinical Oncology
- Key NS, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2023;41(16):3063-3071 (PMID 37075273) (2023), American Society of Clinical Oncology
- Hesketh PJ, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol 2020;38(24):2782-2797 (PMID 32658626) (2020), American Society of Clinical Oncology
- Loprinzi CL, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol 2020;38(28):3325-3348 (PMID 32663120) (2020), American Society of Clinical Oncology
- American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2026 (classification of diabetes, including diabetes of the exocrine pancreas) (2026), American Diabetes Association
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force

## Follow-up

- Interim CT in two weeks. Cycles 5 and 6 every two weeks. Restaging CT and review after cycle 6. Call at once for fever of 38.0 °C or more, diarrhea not controlled by loperamide, bleeding, or yellow eyes. **S**
- Next scheduled visit 1963-08-10: after six cycles: restaging CT and CA 19-9, decision for surgery, and preparation for pancreaticoduodenectomy. **S**
